G-CSF-induced myeloid differentiation of 32Dcl3 murine myeloblast cells is antagonized by concurrent exposure to interleukin-3 (IL-3) or by oncogenic transformation of 32Dcl3 by src-or abl-oncogenes which render the cells IL-3-independent. Recent reports have linked G-CSF-mediated differentiation to the ability of G-CSF to activate Stat3. We hypothesized that IL-3 suppresses 32Dcl3 differentiation in part through disruption of G-CSF-Stat signalling. We report that IL-3 inhibited the ability of G-CSF to induce Stat3 DNA binding. Moreover, we find that G-CSF activation of Stat3 binding to DNA is biphasic, peaking at 15-30 min and again at 6-8 h; both peaks are inhibited by IL-3. Transformation of 32Dcl3 cells by the v-abl oncogene leads to constitutive Stat3 activation and distinctive Stat-DNAbinding patterns which are not affected by G-CSF. Crossmodulation of Stat pathway signalling could be a physiologic mechanism for establishing a hierarchy of growth factor effects upon a cell exposed at once to multiple cytokines.
Introduction
It is unclear exactly how cells can exhibit a dominant response to only one of multiple cytokines in their environment for which they express receptors. Possible mechanisms include differential receptor-ligand affinities, hierarchies of receptor expression, or interactions between cytokine signal transduction pathways or cytokine-induced transcription factors. Two cytokines which influence myeloid differentiation are interleukin-3 (IL-3) and granulocyte colony-stimulating factor (G-CSF). In the 32Dcl3 murine model of myeloid differentiation, IL-3 supports cellular proliferation whereas G-CSF promotes granulocytic differentiation. It has been demonstrated that G-CSF-mediated differentiation is suppressed in these cells in the presence of IL-3;
1-2 similar suppression of differentiation is manifested in cells transformed with oncogenes which render them IL-3-independent, such as v-Abl, 3 and v-Src; 4 bcr-abl is associated with IL-3 independence and altered differentiation. 5 Several signalling mechanisms activated by G-CSF have been described, including the ras-MAPK pathway 6 and the JAK-STAT pathway. 7, 8 Ras activation is not required for G-CSF-mediated differentiation. 9 STATs (signal transducers and activators of transcription) are latent cytoplasmic transcription factors which are tyrosine phosphorylated, dimerize and translocate to the nucleus in response to multiple cytokines (reviewed in Ref. 10) . Several findings support a role for STAT activation in transduction of differentiation signals. Structurefunction analysis has implicated the carboxy-terminal regions of the G-CSF receptor as necessary to transduce signals supporting differentiation. This portion of the receptor contains the domains involved in JAK1 and JAK2 activation and a docking site for Stat protein activation. 7, 11 Stat3 appears to be the major Stat protein involved in G-CSF promotion of granuloCorrespondence: RA Steinman, E1052 Biomedical Science Tower, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; Fax: 412 624 7794 Received 8 July 1998; accepted 8 October 1998 poiesis. A recent report utilizing dominant negative STAT constructs demonstrated a requirement for Stat3 activation by G-CSF for growth arrest and morphologic differentiation. 12 Genes responsive to G-CSF activation of Stat3 have begun to be identified and include Fc␥R1 in neutrophils 13 and fibrinogen in a UT-7-derived differentiation model. 14 Conceivably, the Stat3 signalling pathway could be targeted by cytokines or oncogenes which block 32Dcl3 differentiation. We therefore examined whether disruption of G-CSF-Stat signalling could contribute to the suppression of granulocytic differentiation by IL-3, v-Abl and Bcr-Abl in these cells. These investigations have led to the novel findings of bi-phasic peaks of G-CSF activation of Stat3 DNA-binding activity, and of suppression of G-CSF-Stat3 signalling by IL-3.
Materials and methods

Cytokines and reagents
Recombinant human G-CSF (Amgen, Thousand Oaks, CA, USA) was used at concentrations indicated. WEHI-3B-conditioned media was used as a source of IL-3. This was titered in comparison to murine recombinant IL-3 (R&D Systems, Minneapolis, MN, USA) using tritiated thymidine uptake by NSF-60 cells. 15 The WEHI-CM was used at concentrations shown to reproduce recombinant IL-3 effects on G-CSF differentiation. 2 Okadaic acid was obtained from Life Technologies (Gaithersburg, MD, USA).
Cell lines
32Dcl3 was passaged in RPMI (Life Technologies) supplemented with 10% WEHI-CM or 30% WEHI-CM as indicated, pencillin (50 U/ml), streptomycin (50 U/ml) and 10% heat-inactivated FCS, and maintained in log-phase growth. Vabl transformants of 32Dcl3 were generated by co-electroporation of helper plasmid pNCA and p160 Abl plasmid pTAB1 16 into 32Dcl3 cells as described.
2 Bcr-Abl transfected cells 17 were generously provided by Dr Ursula Matulonis (Dana Farber Cancer Institute, Boston, MA, USA) and ts-Abl transduced 32D cells (RK3) were a gift from Dr John Cleveland (St Judes Research Center) and have previously been described. 2, 18 ts-Abl cells were maintained in 10% WEHI-CM at the nonpermissive (39°C) temperature; this was washed out 3 h prior to G-CSF addition in experiments as described in the text.
Northern blot analysis
Total RNA was extracted from cell lines by solubilization in 4 M guanidium isothiocyanate followed by centrifugation through a cesium chloride cushion. Total RNA was then fractionated on agarose-formaldehyde gels, blotted on to nylon, 55 crosslinked and hybridized to random-primed Fc␥R1 probe using procedures as previously described. 2 
Extract preparation and gel shift assay
Cells were washed in PBS and whole cell extracts prepared by resuspending cell pellets in high salt lysis buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 g/ml leupeptin, 1 g/ml aprotinin, 0.5 mM PMSF, 50% glycerol) followed by three rapid freeze-thaw cycles. For gel shift assays, equivalent amounts of extract protein were preincubated for 20 min in binding buffer (fc 15 mM HEPES, pH 7.9, 65 mM Nacl, 1 mM DTT, 0.15 mM EDTA, 8% glycerol) with sonicated salmon sperm DNA (10 g/reaction) followed by 20-min incubation with 0.2 ng end-labelled target sequence, and fractionation on a 4% nondenaturing polyacrylamide gel. Gel shift assays targeted the serum inducible element target (SIE: GATCCATTTCCCGTAAATCGATC) 19 to determine Stat activation. Excess of unlabelled competitor SIE or of Stat1 target sequence was added as indicated. As indicated, gel shift bands were supershifted by 30-min preincubation with antibodies Stat3 (C-20 TransCruz; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Stat5 (C-17 TransCruz; Santa Cruz Biotechnology).
Western blots
Western blots were performed using standard techniques after fractionation of equal microgram amounts of whole cell extract on 10% SDS-PAGE gels. Monoclonal Stat3 antibody (Transduction Labs, Lexington, KY, USA) or polyclonal Stat3 C-20 (above) or G-CSF receptor antibody (M-20; Santa Cruz Biotechnology) were used at 1:200 dilutions and signal detected using chemiluminescence (ECL; Amersham). Phosphorylated Stat was detected using polyclonal antibody to phosphotyrosine-705 in murine stat (Chemicon International, Temecula, CA, USA).
Results
IL
-3 has been shown to suppress G-CSF-mediated differentiation of murine 32Dcl3 cells. This has been manifested by IL-3 blockade of differentiation-associated morphological changes, enzyme activity, growth arrest, 1 and G-CSF receptor upregulation. 2 We examined the effect of concurrent IL-3 addition on G-CSF activation of Fc␥R1 (CD64) expression. Fc␥R1 has been shown to be increased during terminal myeloid differentiation of CD34 cells. 20 Figure 1 demonstrates that Fc␥R1 expression is induced within 24 h of G-CSF addition to 32Dcl3 cells. This induction is suppressed by concurrent addition of IL-3 to the cells. Fc␥R1 expression requires Pu.1 20 which is constitutively expressed and active in 32Dcl3 cells (Steinman, unpublished observations) . Additionally, Fc␥R1 induction by G-CSF involves Stat3 activation. 13 Conceivably, IL-3 could suppress Fc␥R1 activation by G-CSF by altering G-CSF-Stat coupling.
Biphasic Stat3 signalling
We then examined Stat3 activation by G-CSF in these cells. To do this, extracts of asynchronous 32D cells were tested in an electrophoretic mobility shift assay using a radiolabelled c-sis-inducible element (SIE) fragment. 19 This DNA sequence binds Stat3 homodimers (generating a SIF-A band) and Stat 1 homodimers (SIF-C), as well as a Stat1/Stat3 heterodimer (SIF-B). 21 Figure 2 demonstrates that G-CSF generates an SIEbinding activity in these cells which consists of Stat3 homodimers, given the inability of a Stat1-binding site to compete the band ( Figure 2b ) and supershifting of the band with anti-Stat3 antibody ( Figure 2c ). Binding activity peaked with G-CSF addition at a concentration of 30 ng/ml ( Figure 2a and data not shown). Of interest, Stat3 activation in response to G-CSF was biphasic, peaking at 15-30 min and again at 6 h after G-CSF addition. The late peak in Stat3 binding after G-CSF addition could be suppressed by cycloheximide, indicating a requirement for new protein synthesis (data not shown). However, the oscillation in Stat3 binding does not appear to result from changes in total G-CSF receptor protein, which remains relatively constant over this time period (Figure 2d ).
IL-3 suppression of G-CSF-Stat activation
In order to determine whether Stat3 signalling by G-CSF was altered by IL-3, 32Dcl3 cells were washed free of IL-3, rested for 3 h in cytokine-free medium, and then exposed to G-CSF, IL-3 or G-CSF and IL-3 combined for various times before harvest. As shown in Figure 3a , concurrent addition of IL-3 substantially decreases G-CSF activation of Stat3 at 30 min and almost completely prevents Stat3 activation at 6 h. This is not due to alteration in total Stat3 levels, which are relatively constant and shown in Figure 3a . IL-3 suppression of G-CSF activation of Stat3 is dose-dependent. Figure 3b demonstrates 
Stat activation by v-Abl and Bcr-Abl
We then investigated whether the v-abl and bcr-abl oncogenes also suppressed Stat3 activation by G-CSF. Like IL-3 these oncogenes sustain proliferation and inhibit differentiation of 32Dcl3 cells. These experiments were designed to clarify whether suppression of G-CSF activation of Stat3 binding to DNA required the IL-3 receptor or whether the inhibition resulted from a portion of the IL-3 signalling pathway appropriated by these oncogenes. Basal patterns of SIEbinding activity were first determined in these cells. Bcr-Abl transformed 32D cells have been reported to express activated Stat1 and Stat5 constitutively as a direct result of Bcr-Abl function; 22 IL-3 also activates Stat1 and Stat5 in factor-dependent cells, albeit weakly. 22 We first determined binding to radiolabelled SIE fragement of cell extracts from 32D cell transfectants constitutively expressing v-abl (32DAbl), bcr-abl (32DBcrAbl), or a temperature sensitive abl-oncogene (tsAbl) at semipermissive temperature. As shown in Figure 5a , the oncogenetransformed cells constitutively expressed SIE-binding activities. Binding in Bcr-Abl and tsAbl extracts generates a band which comigrates with that generated by interferon-activated Jurkat cells representing a Stat 1 homodimer (Figure 5e) . A faster-migrating band is also prominent in gel shifts using these extracts as well as extracts from Abl-transformed cells (unlabelled arrow, Figure 5e ). The identity of the latter remains under investigation. It can be competed away with cold SIE but we have been unable to demonstrate a supershift with Stat1 or Stat5 antibodies (data not shown). Both of these bands are weakly induced by IL-3. Substantially more binding activity exists in extracts of v-abl transformants than bcr-abl transformants.
G-CSF signalling in v-abl and bcr-abl transformed 32Dcl3
Figure 5b indicates gel shift activity in extracts of cells grown in medium alone or exposed to G-CSF for 20 min. G-CSFinduction of Stat3-binding activity was suppressed in the BcrAbl and tsAbl-32Dcl3 transformants. As in Figure 5a , Abl extracts contain more binding activity that extracts of Bcr-Abl or tsAbl cells grown at 37°C (semipermissive). Abl-extracts do exhibit a weak SIFA band which appears to increase slightly after 20 min of G-CSF exposure; this is not apparent in the other cell lines. In order to determine more clearly whether Stat3 is constitutively active in Abl-transformed 32D cells, Abl extracts were incubated with the SIE target in the presence of supershifting Stat5 or Stat3 antibody (Figure 5c Of note, this immunoreactive Stat3 binding is not enhanced by exposure of Abl-transformed cells to G-CSF. In an attempt to clarify constitutive Stat3 expression by Abl and whether Abl-transformed cell expression interferes with G-CSF augmentation of Stat3 binding, temperature shift experiments were performed using the RK-3 temperature-sensitive Abl transformant of 32Dcl3 cells. These cells have been shown to exhibit IL-3 independence and Abl-tyrosine kinase activity at the permissive (32°C) but not nonpermissive (39°C) temperature. 2, 18 Cells growing in WEHI medium at 37°C were washed and shifted to 32°C or 39°C for either 4 h (lanes 3, 4, 7, 8) or 2 days (lanes 5, 6, 9, 10) prior to stimulation with G-CSF for 15 min. Cells grown 2 days at 39°C were washed free of WEHI 3 hours prior to G-CSF addition. In contrast to 32D cells transformed with wt-Abl, no SIF-A band is apparent in the tsAbl gel shifts even after 2 days at the permissive temperature. There is a suggestion of a G-CSF-induced SIF A band upon G-CSF addition to cells maintained at the nonpermissive temperature (lane 5), though this is decreased compared to the response to G-CSF in untransfected 32Dcl3 cells (lane 1). We also examined late G-CSF-induced Stat3 activation in oncogene-transformed cells exposed to G-CSF for 6 h ( Figure 5e ). As in the case of the shorter exposure, no marked activation of Stat3 binding activity occurs in response to G-CSF in these cells.
Because the gel-shift pattern of Abl-expressing cells differed from that of G-CSF-exposed cells, we immunoblotted for phospho-Stat3 and for total Stat3 in order to ensure that no aberrant isoforms were expressed. Characteristic Stat3-␣ and Stat3-␤ bands were apparent in the Abl-expressing cells; both isoforms were phosphorylated (Figure 6b ). An additional slowly migrating phosphorylated band, possibly indicating cross-reactivity of the abl oncogene product, did not crossreact with monoclonal antibody against Stat3. The Stat3 phosphorylation pattern of the Abl-transformants was similar to that in wild-type 32Dcl3 cells exposed to G-CSF (Figure 6a ). It is conceivable that G-CSF has little effect on v-Abl transformants because all of the Stat3 is constitutively phosphorylated.
Inhibition of Stat3 phosphorylation by IL-3
Disruption of Stat3-DNA complex formation could result from interruption of the Stat3 signalling pathway at several points. IL-3 could disrupt the ability of G-CSF to phosphorylate Stat3. Alternatively, IL-3 transduced signals could interrupt Stat3 homodimer formation through alternative complex formation, or could interfere with Stat3 binding to specific DNA targets. To help clarify this mechanism, we analyzed Stat3 phosphorylation by G-CSF in the presence and absence of IL-3. As shown in Figure 6 , G-CSF leads to significant phosphorylation of both Stat3 isoform in 32D cells. No phosphorylation occurs following addition of IL-3. In the presence of both IL-3 and G-CSF, immediate phosphorylation of Stat3 is not impaired, but the late expression of Stat3 clearly is blocked by IL-3 ( Figure 6a ).
Discussion
Suppression of differentiation in myeloid leukemias may involve aberrant appropriation of signalling pathways which regulate the pace of differentiation in myelopoiesis. The murine 32Dcl3 myeloid differentiation model offers an opportunity to explore antagonistic actions of IL-3 and G-CSF on differentiation. We have previously reported that upregulation of G-CSF receptor message by G-CSF is inhibited by IL-3 in 32Dcl3 cells. 2 This suggests that IL-3 interferes with transcriptional activation signals transduced by the G-CSF receptor. Several reports have shown that G-CSF activates Stat3 and that this contributes to G-CSF-mediated differentiation. We therefore investigated whether IL-3 disrupted the coupling of G-CSF to Stat3 activation. Because IL-3 effects on 32Dcl3 differentiation and proliferation can be mimicked by tyrosine kinase oncogenes 5, 25, 26 we also investigated the effects of BcrAbl and v-Abl expression on G-CSF activation of Stat3 in these cells.
Our findings demonstrate for the first time that Stat3 activation by G-CSF is suppressed by IL-3. Inhibition is dosedependent and does not involve alteration of either Stat3 or G-CSF receptor protein expression. Similar crosstalk has been reported between IL-6 and GM-CSF pathways in human monocytes. 27 The ability of IL-3 to interfere with G-CSF signalling at an early point in the G-CSF transduction pathway is an effective mechanism for simultaneous suppression of multiple G-CSF-responsive genes. We have shown that IL-3 inhibits G-CSF phosphorylation of Stat3 at tyrosine 705 within 2 h of G-CSF addition ( Figure 6 and data not shown). Mechanisms to account for this inhibition include interference at the level of G-CSF receptor availability or phosphorylation, or Jak1 phosphorylation. Studies to clarify further the mechanism of IL-3 interference with G-CSF signalling are underway. One mechanism through which G-CSF-induced Stat3 signals can be extinguished is through a negative feedback loop involving Stat-3 transcriptional upregulation of Stat-induced STAT inhibitor (SOCS-1, also known as SSI-1 or JAB). [28] [29] [30] This induction occurs 30-60 min after cytokine induction 29 which is compatible with the early decrease in Stat3 activity seen in our 32D cells. IL-3 has not been noted to induce SSI-1 in murine NFS60 cells, 29 and would not be expected to induce it in our cells in which IL-3 does not cause Stat3 phosphorylation. Nonetheless, IL-3 induction of a similar Stat3-inhibitor remains a possibility. Studies to clarify further the mechanism of IL-3 interference with G-CSF signalling are underway.
The biphasic Stat3 activation pattern induced by G-CSF is intriguing. Induction of Stat3 within minutes of G-CSF addition to 32Dcl3 cells has been noted previously; 7,8 our finding of a second wave of Stat3 activation hours after the initial G-CSF addition extends those observations. Distinct subsets of genes could be activated by Stat3 binding within minutes of G-CSF, as opposed to those activated hours later once early signals have been transduced. Biphasic Stat signalling could facilitate synergy between cooperating components of transcriptional machinery 31, 32 available in temporally distinct windows. The induction pattern is unlikely to be an epiphenomenon of cell cycle stage, since the cells used were asynchronous. Although total G-CSF receptor protein is not altered in this timeframe, the biphasic signal could conceivably reflect receptor internalization. Cycloheximide inhibits the late signalling event, suggesting that labile intermediaries or perhaps ongoing G-CSF receptor synthesis, is required to generate the late signal. Okadaic acid inhibits late signalling through a different mechanism than cycloheximide because levels of Stat3 and G-CSF receptor are constant in okadiac acid-treated cells over this timeframe. The ability of okadaic acid to inhibit this late activation could indicate that phosphorylated mediators (eg tyrosine phosphatase 1D 33 ) oppose G-CSF-Stat activation. Additional experiments will be required to clarify this.
We do not observe significant Stat3 binding of DNA induced by IL-3 alone in these cells. Interestingly, Chaturvedi et al 34 have recently reported IL-3 activation of Stat3 in 32Dcl3 cells mediated through c-src, rather than Jak kinases. In that study IL-3 induced protein binding to the Stat3 binding element derived from the c-sis-promoter (GATCCCTTCTGGGAATTCCTAGATC). This report raises the intriguing prospect that distinct Stat3 transducing pathways could interact at the promoter level to affect different Stat3 binding elements in different ways. On the other hand, the lack of IL-3 phosphorylation of Stat3 at tyrosine 705 in our studies may indicate that the differences observed between Chaturvedi et al and our findings arise from passage of independent 32Dcl3 lines over time. This would be consistent with a report from another laboratory that IL-3 did not activate Stat3 in 32Dcl3 cells. 35 Clarification of precise mechanisms involved in disruption of G-CSF-Stat3 coupling could be important to understanding differentiation blockade in myeloid leukemias. 38, 39 Extracts from the Bcr-Abl and v-Abl transfectants also generate Stat1 homodimer bands which are induced to a much lesser degree by IL-3 treatment of 32Dcl3 cells. In Abl-transformed cells, upregulation of Stat3 DNA binding by G-CSF is dampened, and most Stat3 resides in heterodimeric complexes rather than in the SIF-A (Stat3 homodimer) complexes characteristic of G-CSF activation.
Blotting of the 32Dcl3 cells for Stat3 gave rise to a doublet on Western blots of protein extracts well-separated on 10% gels. This migration pattern was characteristic of the alphaand beta-Stat isoforms. Both Stat3 alpha and beta retain DNAbinding and transcriptional activity 40 although the betaisoform has been suggested as a dominant-negative form based on its lesser ability to activate transcription. 41 Such a role would suggest that beta would be the dominant Stat3 isoform to be activated by the abl-oncogene. Our data does not demonstrate this, however. The altered Stat3 DNA-binding pattern seen in the presence of abl-transduction may nonetheless be correlated with transcriptional repression and may arise from novel Stat interactions at the target site.
Suppression of differentiation by both IL-3 and by v-Abl and bcr-abl oncogenes may involve attenuation of G-CSF-induced binding of Stat3 to promoter elements. In each instance, distinct mechanisms appear to be involved. IL-3 decreases the magnitude of Stat3 signalling by G-CSF by decreasing Stat3 phosphorylation. In contrast, Stat3 is constitutively phosphorylated in Abl-transformants. IL-3 does not appear to redirect G-CSF-induced Stat3 homodimeric complexes into Stat1:3 heterodimers. In contrast, in Abl-transformed cells, gel shift analysis indicates sequestration of Stat3 into heterodimers with Stat1 (SIF-B bands); these are constitutively present. It is likely that Bcr-Abl and Abl oncogenes also promote the generation of alternative Stat-DNA binding complexes which could cause the repression of promoter sites otherwise activated by Stat3 homodimers. Further study will clarify whether these aberrant interactions at one Stat3-responsive element are generalizable to all sites capable of binding activated Stat3.
The 32Dcl3 system is a useful model in studying how cytokines induce myeloblasts to switch from proliferation to differentiation. This transition may balance the effects of cytokines which inhibit differentiation, sustaining or expanding the progenitor pool, and those promoting differentiation. Our finding that IL-3 inhibits G-CSF induction of Stat3 binding to DNA supports the notion that interacting cytokine signalling pathways contribute to the cross-talk which sustains this balance. Aberrant activation of such differentiation-restraining pathways may characterize the oncogenic blockade to differentiation manifested in leukemias.
